Nuvectis Pharma, Inc. Reports Fiscal Year 2023 EPS $(1.43) Vs $(1.51) YoY

3/5/24 8:21:39 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NVCT alert in real time by email

NUVECTIS PHARMA, INC.STATEMENT OF OPERATIONS(USD in thousands, except per share and share amounts)For the year endedFor the year endedDecember 31, 2023December 31, 2022OPERATING EXPENSES:Research and development15,38013,227General and administrative7,5176,007OPERATING LOSS(22,897)(19,234)Finance income637149NET LOSS(22,260)(19,085)NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS(22,260)(19,085)BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING(1.43)(1.51)Basic and diluted weighted average number of common shares outstanding15,556,65512,657,651

Get the next $NVCT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NVCT

Date	Price Target	Rating	Analyst
7/13/2022	$21.00	Buy	Ladenburg Thalmann
3/2/2022	$14.00	Buy	HC Wainwright & Co.

More analyst ratings

$NVCT
Press Releases

Fastest customizable press release news feed in the world

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
NXP800 demonstrated single agent activity New dosing schedule successfully minimized thrombocytopenia Fort Lee, NJ, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported encouraging data from the Phase 1b study evaluating NXP800 in patients with platinum resistant ARID1a-mutated ovarian cancer. Platinum-resistant, ARID1a-mutated ovarian cancer is a serious condition that carries a poor prognosis with an estimated life expectancy of approximately one year from diagnosis.
11/14/24 7:00:00 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancersNXP900 Phase 1a dose escalation study progressing as planned, 4 escalation cohorts completed with no DLTs, dose escalation continues FORT LEE, N.J., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter
11/5/24 7:00:21 AM ET
$NVCT
Biotechnology: Pharmaceutical Preparations
Health Care
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
Nuvectis Pharma (NASDAQ:NVCT) continues to make strides in precision oncology, gaining momentum following presentations last week at the AACR-NCI-EORTC Symposium where its drug candidate NXP900 demonstrated strong synergy with ALK inhibitors in non-small cell lung cancer (NSCLC) cells that despite being driven by ALK fusions, are resistant to treatment with the market leading ALK Inhibitors, alectinib and lorlatinib, showcasing NXP900's potential to address resistance mechanisms in NSCLC. Also, with the growing anticipation of the data update from NXP800 expected soon from the Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, Nuvectis is positioning itself at the forefron
10/28/24 8:21:00 AM ET
$NUVL
$NVCT
$SMMT
Biotechnology: Pharmaceutical Preparations
Health Care

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 EPS $(1.43) Vs $(1.51) YoY

Chat with this insight

Recent Analyst Ratings for
$NVCT

$NVCT
Press Releases

Fastest customizable press release news feed in the world

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

$NVCT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Science & Business Off Poradosu Enrique bought $9,980 worth of shares (2,000 units at $4.99), increasing direct ownership by 0.13% to 1,506,319 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $98,400 worth of shares (20,000 units at $4.92), increasing direct ownership by 0.62% to 3,266,424 units (SEC Form 4)

Bentsur Ron bought $13,076 worth of shares (1,940 units at $6.74), increasing direct ownership by 0.06% to 3,246,424 units (SEC Form 4)

$NVCT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

SEC Form SC 13G filed by Nuvectis Pharma Inc.

$NVCT
SEC Filings

SEC Form 10-Q filed by Nuvectis Pharma Inc.

Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$NVCT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

HC Wainwright & Co. initiated coverage on Nuvectis Pharma with a new price target

$NVCT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Science & Business Off Poradosu Enrique bought $9,980 worth of shares (2,000 units at $4.99), increasing direct ownership by 0.13% to 1,506,319 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $98,400 worth of shares (20,000 units at $4.92), increasing direct ownership by 0.62% to 3,266,424 units (SEC Form 4)

Vice President, Finance Carson Michael J. sold $22,478 worth of shares (2,755 units at $8.16) and was granted 63,373 shares, increasing direct ownership by 222% to 87,918 units (SEC Form 4)

$NVCT
Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target

Nuvectis Pharma Q1 EPS $(0.25) Beats $(0.40) Estimate

Nuvectis Pharma's NXP900 Demonstrates Robust Activity In Non-Small Cell Lung Cancer Cell Lines

Nuvectis Pharma, Inc. Reports Fiscal Year 2023 EPS $(1.43) Vs $(1.51) YoY

Chat with this insight

Recent Analyst Ratings for $NVCT

$NVCT Press Releases

Fastest customizable press release news feed in the world

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

$NVCT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Science & Business Off Poradosu Enrique bought $9,980 worth of shares (2,000 units at $4.99), increasing direct ownership by 0.13% to 1,506,319 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $98,400 worth of shares (20,000 units at $4.92), increasing direct ownership by 0.62% to 3,266,424 units (SEC Form 4)

Bentsur Ron bought $13,076 worth of shares (1,940 units at $6.74), increasing direct ownership by 0.06% to 3,246,424 units (SEC Form 4)

$NVCT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Nuvectis Pharma Inc.

SEC Form SC 13G/A filed by Nuvectis Pharma Inc. (Amendment)

SEC Form SC 13G filed by Nuvectis Pharma Inc.

$NVCT SEC Filings

SEC Form 10-Q filed by Nuvectis Pharma Inc.

Nuvectis Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Nuvectis Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

$NVCT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ladenburg Thalmann initiated coverage on Nuvectis Pharma with a new price target

HC Wainwright & Co. initiated coverage on Nuvectis Pharma with a new price target

$NVCT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Science & Business Off Poradosu Enrique bought $9,980 worth of shares (2,000 units at $4.99), increasing direct ownership by 0.13% to 1,506,319 units (SEC Form 4)

Chairman & CEO Bentsur Ron bought $98,400 worth of shares (20,000 units at $4.92), increasing direct ownership by 0.62% to 3,266,424 units (SEC Form 4)

Vice President, Finance Carson Michael J. sold $22,478 worth of shares (2,755 units at $8.16) and was granted 63,373 shares, increasing direct ownership by 222% to 87,918 units (SEC Form 4)

$NVCT Market Insights

Live Market Insights

HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target

Nuvectis Pharma Q1 EPS $(0.25) Beats $(0.40) Estimate

Nuvectis Pharma's NXP900 Demonstrates Robust Activity In Non-Small Cell Lung Cancer Cell Lines

Recent Analyst Ratings for
$NVCT

$NVCT
Press Releases

$NVCT
Insider Purchases

$NVCT
Large Ownership Changes

$NVCT
SEC Filings

$NVCT
Analyst Ratings

$NVCT
Insider Trading

$NVCT
Market Insights